Compare Ascendis Pharma A/S (ASND) vs Etsy Inc (ETSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Etsy Inc — how do they compare? Ascendis Pharma A/S trades at $256.72 (market cap $16.67B), while Etsy Inc trades at $79.21 (market cap $7.29B). The key difference: Ascendis Pharma A/S is far larger — about 2.3× Etsy Inc's market cap. Which is the better fit depends on your goals.
| ASND | ETSY | |
|---|---|---|
Market Cap | $16.67B | $7.29B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $86.47 |
52-Week Low | $189.74 | $44.05 |
Enterprise Value | $17.04B | $9.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
ETSY trades at $80.40, down 6.02% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong Q2 2026 results with EPS of $0.98 beating expectations of $0.747, while announcing a 12% workforce reduction and $2 billion share repurchase program. Revenue trends show modest growth from $2.6B in 2022 to $2.9B in 2025, though net income margins have compressed from 11.19% in 2023 to 5.65% in 2025.
The outlook remains mixed with analyst consensus at Buy (46.7%) versus Hold (46.7%) and an $85.71 price target offering 6.6% upside. Key risks include high debt levels ($2.29B long-term debt), competitive pressures, and execution of restructuring. Positive catalysts include AI integration progress and operational efficiency improvements driving GMS growth acceleration to 7.5% year-over-year.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →
